Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (mogad) Clinical Trials
3 recruiting trials for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (mogad). Eligibility criteria explained in plain English.
TrialFinderData lists 3 Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (mogad) clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Every phased trial in this set is Early Phase 1 (1 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.
Research is led by Third Affiliated Hospital, Sun Yat-Sen University (1), Tongji Hospital (1), University of Bern (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is CT103A cells (biological, 1 trial), followed by Cyclophosphamide and fludarabine.
Track Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (mogad) trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Cohort Study on Neuroimmune Diseases in the Reproductive Age
Neuroimmune diseases are more prevalent among women of reproductive age. Studies have shown that neuroimmune diseases may impact fertility. Therefore, effective management of...
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous...
Antibody-mediated inflammatory diseases of the nervous system (also known as autoimmune diseases of the nervous system) are autoimmune diseases in which autoimmune cells and...
Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)
The Swiss-Ped-IBrainD is a national patient registry that collects information on diagnosis, symptoms, treatment, and follow-up of pediatric patients with an inflammatory brain...
Explore Other Conditions
Frequently Asked Questions
There are currently 3 clinical trials for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (mogad), with 3 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (mogad), review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (mogad), representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.